新生儿红斑狼疮相关进展研究
Study on the Progress Related to Neonatal Lupus Erythematosus
DOI: 10.12677/acm.2024.1441338, PDF, HTML, XML, 下载: 29  浏览: 47 
作者: 谭术军, 努尔亚·热加甫*:新疆医科大学,新疆 乌鲁木齐
关键词: 新生儿新生儿红斑狼疮Newborn Neonatal Lupus Erythematosus
摘要: 新生儿红斑狼疮(Neonatal lupus erythematosus, NLE)是一种罕见的结缔组织病,可以影响多个器官,包括皮肤、心脏、肝脏、骨髓和中枢神经系统。其发病机制与母体内自身抗体(抗干燥综合征A抗体和抗干燥综合征B抗体)通过胎盘进入胎儿体内引起的多器官、系统免疫损伤有关。NLE的主要临床表现是皮肤损害和先天性心脏传导阻滞(Congenital heart block, CHB),也可能累及肝脏和血液系统。罕见的情况下,多个系统同时受累。先天性心脏传导阻滞是NLE最严重的表现,病死率高,预后较差。因此,对具有高危因素的母亲,应加强围产期管理,以便早期诊断和干预。为了改善NLE患儿的预后,我们需要进一步深入研究其发病机制和防治策略。本综述对新生儿红斑狼疮在病因、临床表现、治疗和预后等方面的研究进展进行的总结。
Abstract: Neonatal lupus erythematosus (NLE) is a rare connective tissue disease that can affect multiple organs, including skin, heart, liver, bone marrow, and central nervous system. Its pathogenesis is related to the multi-organ and systemic immune damage caused by maternal autoantibodies (anti-Sjögren syndrome A antibodies and anti-Sjögren syndrome B antibodies) entering the fetus through the placenta. The main clinical manifestations of NLE are skin lesions and congenital heart block (CHB), which may also involve the liver and blood system. Rarely, multiple systems are affected simultaneously. Congenital heart block is the most serious manifestation of NLE, with high mortality and poor prognosis. Therefore, perinatal management should be strengthened for mothers with high-risk factors to facilitate early diagnosis and intervention. In order to improve the prognosis of children with NLE, we need to further study its pathogenesis and prevention and treatment strategies. This review summarizes the research progress on the etiology, clinical manifestations, treatment and prognosis of neonatal lupus erythematosus.
文章引用:谭术军, 努尔亚·热加甫. 新生儿红斑狼疮相关进展研究[J]. 临床医学进展, 2024, 14(4): 2626-2630. https://doi.org/10.12677/acm.2024.1441338

1. 病因

目前认为NLE的致病机制主要是母体内的SSA和SSB抗体IgG进入胎儿体内形成抗原抗体复合物,导致器官损害,引起疾病 [1] [2] 。除此之外,遗传因素和免疫调节异常等因素也可能与NLE的发生相关。最新研究表明 [3] ,胎儿易感基因DNAJC6与NLE发生有关,并且对心脏发育和功能具有关键影响。这项研究揭示了CHB发生的遗传机制,并提供了新的治疗策略可能性。虽然研究结果需要进一步验证,但对于CHB的研究和治疗有着积极意义,并为未来的研究和临床实践指明了新方向。HLA基因位点的变异与胎儿发生CHB的易感性相关,包括特定位点的变异增加或减少CHB的风险 [4] 。这些变异可能影响胎儿免疫系统功能,导致CHB的发生。在评估CHB风险时需要考虑其他因素。研究结果为NLE的病因提供新视角,并为未来治疗提供潜在的靶点。需要进一步研究验证,包括更大规模的临床实验、分子生物学研究和动物模型,以确定HLA基因位点变异与NLE之间的确切关联和作用机制。

2. 临床表现

2.1. 常见临床表现

NLE常见于面部、颈部和手部的皮肤病变 [5] ,表现为红斑、斑块、结节和水泡等症状。这些皮肤问题往往被误诊为其他疾病而被忽视,但同时还可能引发心脏并发症,其中胎儿心动过缓是一个早期征兆。即使母亲没有明显症状,超过半数血清检测阳性的母亲也可能患有NLE。因此,医务人员应当警惕NLE,及时诊断和治疗,尤其在出现胎儿心动过缓或皮肤症状时。疫苗接种可能会引发症状加重的现象 [6] ,但同时也具有保护患儿免受其他疾病侵害的重要作用。在考虑接种疫苗时,应综合考虑患儿的免疫状态、风险以及疫苗的安全性,以确保在最大程度上保护患儿免受感染的同时降低接种风险。这样才能在保护患儿健康的前提下有效预防潜在的疾病风险。CHB是NLE中最严重的并发症之一,完全性CHB甚至可能导致死亡率高达30% [7] 。房室传导阻滞可分为不同程度,包括I度、II度和III度。在某些情况下,I度和II度房室传导阻滞可被缓解或完全消失,但III度房室传导阻滞通常是不可逆的 [8] 。一项研究表明,NLE患者中,CHB是最常见的临床表现之一,约占65.2%比例,高于皮肤损伤的发生率 [9] 。NLE可能对心脏造成损害,包括心内膜弹力纤维增生症、瓣膜病、心肌炎、扩张性心肌病、心包积液和心律失常等 [10] 。同时,婴儿患有新生儿红斑狼疮时可能会出现中性粒细胞减少、血小板减少,甚至再生障碍性贫血或溶血性贫血。此外,新生儿红斑狼疮也可能对肝胆系统产生影响,导致胆汁淤积、肝功能衰竭、转氨酶升高以及肝脾肿大 [11] [12] 。尽管黄疸在NLE患者中不常见,但仍有可能发生。

2.2. 罕见的表现

除了典型的临床症状外,NLE还可能呈现一些罕见表现。这些罕见表现对于医生尽早诊断和治疗疾病起着重要作用。例如,当肝脏功能受损导致新生儿出现血红蛋白沉淀症时,可能会出现典型的“浣熊眼”或“猫头鹰眼睛”体征 [13] 。Song等人的研究发现 [14] ,NLE中发热的患病率高达25.9%。尽管发热在一些NLE患儿中可能出现,但却鲜有文献提及此症状。这可能是因为发热在患有NLE的婴儿中严重程度和频率不一,并且发热本身也是一种非特异性症状,容易与其他感染性疾病混淆。因此,当婴儿出现不明原因的发热,特别是伴有皮疹时,应当考虑到罕见的病因,如NLE [15] [16] 。在Ammar等人的病例报告中,患儿患有新生儿狼疮肝病的同时还伴发了新生儿血色素沉着症,这是一种罕见的新生儿疾病 [13] 。新生儿血色素沉着症的特征是铁在血液中异常沉积,导致皮肤、黏膜和内脏出现棕色色素沉着。经过类固醇治疗,患儿的病情最终得到了一定程度的缓解。M.G. Kartheeka [17] 报道了一例少见病例,患者出现高胆红素、升高的转氨酶和凝血紊乱等多种并发症。经过IVIG和换血治疗效果不明显,医生建议将其转介至肝脏移植中心。尽管TORCH检测结果正常,但暗示可能存在其他导致急性肝功能衰竭的因素。这种情况表明这种病例的治疗效果较差,因此需要进一步的诊断和治疗来明确引起急性肝功能衰竭的确切原因。先天性疤痕是一种罕见的疤痕 [18] ,通常在出生时就已经存在。这种疤痕的主要特征包括红斑和色素增多,常见于面部、躯干和上肢。对于这种疤痕,医生应该考虑是否与NLE有关,并且应该尽早采取治疗措施。

3. 诊断

根据美国风湿病协会的诊断标准 [19] ,诊断新生儿红斑狼疮需要满足一定条件:新生儿出现先天性心脏传导阻滞且伴有阳性的抗SSA抗体和/或抗SSB抗体,或者新生儿出现相关皮肤损害经过确定且伴有上述阳性抗体。对于表现出环形红斑、皮肤病变、心电图异常、贫血和血小板减少的新生儿,应该怀疑可能存在新生儿红斑狼疮,并了解母亲是否有自身免疫性疾病史 [20] 。尽管胎儿心磁图是一种新型无创检查手段,但其临床应用受到限制,而超声心动图则成为临床上首选的诊断和鉴别胎儿心律失常的方法,因其技术成熟、可靠性高、经济便捷 [21] 。

4. 治疗及预后

对于NLE患者来说,大多数症状是暂时的,只有心脏受损是一个长期问题。目前尚无有效的治疗方法来应对III度房室传导阻滞(CHB)造成的心脏损害,严重情况下可能需要安装心脏起搏器 [22] ,可以通过锻炼来改善缓慢的心率,不过需要监测抗体引起的心脏问题的风险。定期进行随访和提供心理支持也是至关重要的。研究表明,使用羟氯喹(HCQ)可以有效降低CHB的复发率 [23] [24] [25] [26] [27] 。针对抗SS-A和抗SS-B阳性的孕妇,在妊娠初期给予HCQ治疗可能是一个有效的策略。因此,在孕妇中预防先天性房室传导阻滞的发生时,可以考虑使用HCQ治疗。怀孕期间,特别是在怀孕16~24周时,进行产前超声等检查非常重要,以便及早发现房室传导阻滞。一旦这种情况被确认,及时采取产前干预措施是必要的,例如使用地塞米松、硫酸羟氯喹、丙种球蛋白以及血浆置换等治疗方法,以确保胎儿的健康 [24] 。静脉注射免疫球蛋白(IVIG)在治疗儿童系统性红斑狼疮(SLE)中被广泛使用,尤其在危重症患者中效果更为显著 [28] [29] ,根据欧洲指南的建议,IVIG可向所有危重症儿童SLE患者推荐,表明IVIG是一种有效的治疗选择 [29] 。在张利等人的研究中,他们选取了45例新生儿红斑狼疮(NLE)患者,研究了2010年1月至2020年12月间对他们进行静脉注射人免疫球蛋白(IVIG)治疗的效果。研究结果表明,IVIG治疗可以显著改善患者的皮疹、肝功能损伤和发热等症状,但在处理血小板减少和Ⅰ度房室传导阻滞方面效果不尽如人意。总的来看,IVIG在治疗儿童SLE方面显示出一定的疗效,因此可以被认为是一种有效的治疗选择 [30] 。

5. 结语

文献指出,一些患者可能出现罕见症状,这可能是NLE的症状之一。因此,当出现这些罕见症状时,应该考虑到可能是NLE。心室传导阻滞是新生儿狼疮最严重的并发症之一,会导致心脏功能异常。因此,每位孕妇都应该接受抗核抗体测试,以便早期发现和治疗NLE,不管有无症状。大部分新生儿狼疮的症状通常在出生后才会显现出来,因此目前唯一的诊断方法是通过胎儿超声心动图检查来观察心脏传导系统是否异常,以确定是否存在NLE。推广孕期服用羟氯喹可能有助于预防NLE的发生。尽管NLE的诊断有一定困难,但疾病标志物在诊断和预测NLE方面非常重要。为了提供更准确、及时的诊断和干预措施,需要进一步研究NLE的诊断和治疗。

NOTES

*通讯作者。

参考文献

[1] Costedoat-Chalumeau, N., Morel, N., Fischer-Betz, R., et al. (2019) Routine Repeated Echocardiographic Monitoring of Fetuses Exposed to Maternal Anti-SSA Antibodies: Time to Question the Dogma. Lancet Rheumatol, 1, E187-E193.
https://doi.org/10.1016/S2665-9913(19)30069-4
[2] Vanoni, F., Lava, S.A.G., Fossali, E.F., et al. (2017) Neonatal Systemic Lupus Erythematosus Syndrome: A Comprehensive Review. Clinical Reviews in Allergy & Immunology, 53, 469-476.
https://doi.org/10.1007/s12016-017-8653-0
[3] Meisgen, S., Hedlund, M., Ambrosi, A., et al. (2022) Auxilin Is a Novel Susceptibility Gene for Congenital Heart Block Which Directly Impacts Fetal Heart Function. Annals of the Rheumatic Diseases, 81, 1151-1161.
https://doi.org/10.1136/annrheumdis-2021-221714
[4] Meisgen, S., Östberg, T., Salomonsson, S., et al. (2014) The HLA Locus Contains Novel Foetal Susceptibility Alleles for Congenital Heart Block with Significant Paternal Influence. Journal of Internal Medicine, 275, 640-651.
https://doi.org/10.1111/joim.12179
[5] Gryka-Marton, M., Szukiewicz, D., Teliga-Czajkowska, J., et al. (2021) An Overview of Neonatal Lupus with Anti-Ro Characteristics. International Journal of Molecular Sciences, 22, Article 9281.
https://doi.org/10.3390/ijms22179281
[6] Ishikawa, M., Mori, T. and Yamamoto, T. (2020) Neonatal Lupus Erythematosus Exacerbated by Vaccination. The Journal of Dermatology, 47, 1450-1453.
https://doi.org/10.1111/1346-8138.15588
[7] Yu, Y., Du, L., Pan, J., et al. (2016) A 10-Year Retrospective Study of Neonatal Lupus Erythematous in China. Asian Pacific Journal of Allergy and Immunology, 34, 174-178.
https://doi.org/10.12932/AP0671.34.2.2016
[8] Yildirim, A., Tunaoolu, F.S. and Karaaoac, A.T. (2013) Neonatal Congenital Heart Block. Indian Pediatrics, 50, 483-488.
https://doi.org/10.1007/s13312-013-0156-3
[9] Erden, A., Fanouriakis, A., Kiliç, L., et al. (2020) Geoepidemiology and Clinical Characteristics of Neonatal Lupus Erythematosus: A Systematic Literature Review of Individual Patients’ Data. Turkish Journal of Medical Sciences, 50, 281-290.
https://doi.org/10.3906/sag-1910-39
[10] Brito-Zerón, P., Izmirly, P.M., Ramos-Casals, M., et al. (2015) The Clinical Spectrum of Autoimmune Congenital Heart Block. Nature Reviews Rheumatology l, 11, 301-312.
https://doi.org/10.1038/nrrheum.2015.29
[11] Chang, C. (2012) Neonatal Autoimmune Diseases: A Critical Review. Journal of Autoimmunity, 38, J223-J238.
https://doi.org/10.1016/j.jaut.2011.11.018
[12] Chang, C. (2013) The Pathogenesis of Neonatal Autoimmune and Autoinflammatory Diseases: A Comprehensive Review. Journal of Autoimmunity, 41, 100-110.
https://doi.org/10.1016/j.jaut.2012.12.010
[13] Khayat, A.A. and Alkhaldi, A.J. (2022) Neonatal Lupus Presenting with Neonatal Hemochromatosis-Like Liver Disease That Responded to Steroids: A Case Report. BMC Pediatrics, 22, Article No. 630.
https://doi.org/10.1186/s12887-022-03713-4
[14] Song, J.Y., Park, S.E., Byun, J.H., et al. (2021) Neonatal Lupus Erythematosus as a Rare Cause of Fever in Young Infants. Journal of Clinical Medicine, 10, Article 3195.
https://doi.org/10.3390/jcm10143195
[15] Shin, Y., Kang, J.M. and Ahn, J.G. (2020) A Case of Neonatal Lupus Presenting with Fever and Skin Rash in a 47-Day-Old Girl. Pediatric Emergency Medicine, 8, 38-41.
https://doi.org/10.22470/pemj.2020.00171
[16] Shiiya, C. and Ota, M. (2017) Facial Rash, Fever, and Anemia in A Newborn. JAMA: The Journal of the American Medical Association, 317, 2125-2126.
https://doi.org/10.1001/jama.2017.3058
[17] Kartheeka, M.G., Kumaran, U., Rao, N.N., et al. (2021) Neonatal Lupus Erythematosus Presenting as Neonatal Acute Liver Failure. Indian Journal of Pediatrics, 88, 375-376.
https://doi.org/10.1007/s12098-020-03552-0
[18] Khurana, A., Maria, A., Sardana, K., et al. (2019) Congenital Scars: A Rare Presentation of Neonatal Lupus. ADC Fetal & Neonatal Edition, 104, F630.
https://doi.org/10.1136/archdischild-2019-317141
[19] Derdulska, J.M., Rudnicka, L., Szykut-Badaczewska, A., et al. (2021) Neonatal Lupus Erythematosus—Practical Guidelines. Journal of Perinatal Medicine, 49, 529-538.
https://doi.org/10.1515/jpm-2020-0543
[20] Johnson, B. (2014) Overview of Neonatal Lupus. Journal of Pediatric Health Care, 28, 331-341.
https://doi.org/10.1016/j.pedhc.2013.07.015
[21] Zhou, K.Y. and Hua, Y.M. (2017) Autoimmune-Associated Congenital Heart Block: A New Insight in Fetal Life. Chinese Medical Journal, 130, 2863-2871.
https://doi.org/10.4103/0366-6999.219160
[22] Tunaoglu, F.S., Yildirim, A. and Vurali, D. (2010) Isolated Congenital Heart Block. Texas Heart Institute Journal, 37, 579-583.
[23] Izmirly, P.M., Kim, M.Y., Llanos, C., et al. (2010) Evaluation of the Risk of Anti-SSA/Ro-SSB/La Antibody-Associated Cardiac Manifestations of Neonatal Lupus in Fetuses of Mothers with Systemic Lupus Erythematosus Exposed to Hydroxychloroquine. Annals of the Rheumatic Diseases, 69, 1827-1830.
https://doi.org/10.1136/ard.2009.119263
[24] Izmirly, P.M., Costedoat-Chalumeau, N., Pisoni, C.N., et al. (2012) Maternal Use of Hydroxychloroquine Is Associated with a Reduced Risk of Recurrent Anti-SSA/Ro-Antibody-Associated Cardiac Manifestations of Neonatal Lupus. Circulation, 126, 76-82.
https://doi.org/10.1161/CIRCULATIONAHA.111.089268
[25] Martínez-Sánchez, N., Pérez-Pinto, S., Robles-Marhuenda, Á., et al. (2017) Obstetric and Perinatal Outcome in Anti-Ro/SSA-Positive Pregnant Women: A Prospective Cohort Study. Immunologic Research, 65, 487-494.
https://doi.org/10.1007/s12026-016-8888-5
[26] Barsalou, J., Costedoat-Chalumeau, N., Berhanu, A., et al. (2018) Effect of in Utero Hydroxychloroquine Exposure on the Development of Cutaneous Neonatal Lupus Erythematosus. Annals of the Rheumatic Diseases, 77, 1742-1749.
https://doi.org/10.1136/annrheumdis-2018-213718
[27] Izmirly, P., Kim, M., Friedman, D.M., et al. (2020) Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. Journal of the American College of Cardiology, 76, 292-302.
https://doi.org/10.1016/j.jacc.2020.05.045
[28] Hoffmann, J.H.O. and Enk, A.H. (2019) High-Dose Intravenous Immunoglobulin in Skin Autoimmune Disease. Frontiers in Immunology, 10, Article 1090.
https://doi.org/10.3389/fimmu.2019.01090
[29] Enk, A.H., Hadaschik, E.N., Eming, R., et al. (2016) European Guidelines (S1) on the Use of High-Dose Intravenous Immunoglobulin in Dermatology. Journal of the European Academy of Dermatology and Venereology, 30, 1657-1669.
https://doi.org/10.1111/jdv.13725
[30] 张利, 米荣, 王晓颖,等. 静脉注射人免疫球蛋白治疗45例新生儿红斑狼疮的疗效[J]. 中国新药与临床杂志, 2023, 42(6): 378-382.